Population Pharmacokinetics and Pharmacodynamics of Ribavirin in Patients with Chronic Hepatitis C Genotype 1 Infection
- 26 May 2012
- journal article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 14 (3), 571-580
- https://doi.org/10.1208/s12248-012-9368-z
Abstract
We report a population pharmacokinetic (PK) and pharmacodynamic (PD) model of orally administered ribavirin in patients with chronic hepatitis C virus (HCV) infection enrolled in a multicenter clinical trial, including the estimation of covariate effects on ribavirin PK parameters and sustained viral response (SVR). Ribavirin concentrations obtained from 144 patients, consisting of n = 71 African American (AA) and n = 73 Caucasian Americans (CA), during 24 weeks of therapy were best described by a two-compartment model with first-order absorption and elimination parameterized in terms of apparent oral clearance (CL/F), apparent central volume (Vc/F), apparent peripheral volume (Vp/F), and apparent intercompartmental clearance (Q/F). The typical population parameters were CL/F (19.0 L/h), Vc/F (1,130 L), Vp/F (4,020 L), and Q/F (38.6). The Vp/F was approximately 50% greater in AA compared to CA. Significant covariates in the SVR model included IL-28B genotype, homeostasis model assessment of insulin resistance, and ribavirin exposure during the first week (AUC0 − 7). The population PK and logistic regression models both described the observed ribavirin concentration data and SVR data well. These findings suggest that optimization of ribavirin plasma concentrations during the first week of ribavirin dosing is most critical in AA patients in order to increase the rate of SVR, especially those with the IL-28B TT genotype.Keywords
This publication has 33 references indexed in Scilit:
- Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumoursBritish Journal of Clinical Pharmacology, 2011
- Effect of Dietary Purines on the Pharmacokinetics of Orally Administered RibavirinThe Journal of Clinical Pharmacology, 2009
- Diagnosis, management, and treatment of hepatitis C: An updateHepatology, 2008
- Peginterferon Pharmacokinetics in African American and Caucasian American Patients With Hepatitis C Virus Genotype 1 InfectionClinical Gastroenterology and Hepatology, 2008
- Pharmacokinetics of ribavirin in patients with hepatitis C virusBritish Journal of Clinical Pharmacology, 2006
- Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa‐2a (40KD) plus ribavirinBritish Journal of Clinical Pharmacology, 2006
- Black patients with chronic hepatitis C have a lower sustained viral response rate than non‐Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*Journal of Viral Hepatitis, 2005
- Inhibition of glucagon improves splanchnic hyporesponse to terlipressin in cirrhotic rats with blood retention in the gastric lumenJournal of Hepatology, 2005
- Fibrosis and disease progression in hepatitis CHepatology, 2002
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976